MitrAssist

company

About

MitrAssist offers a minimally invasive approach to mitral regurgitation treatment.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$50M
Industries
Biotechnology,Health Diagnostics,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.

MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality.

MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$80M
MitrAssist has raised a total of $80M in funding over 2 rounds. Their latest funding was raised on Dec 3, 2020 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 3, 2020 Series Unknown $50M 1 Detail
Nov 11, 2017 Series Unknown $30M 2 Fosun International Detail

Investors

Number of Lead Investors
Number of Investors
1
2
MitrAssist is funded by 2 investors. Fosun International and Ping An are the most recent investors.
Investor Name Lead Investor Funding Round
Fosun International Yes Series Unknown
Ping An Series Unknown